226 related articles for article (PubMed ID: 36914193)
1. Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study.
Fan Y; Zhu X; Xu C; Ding C; Hu J; Hong Q; Wang J
BMJ Open; 2023 Mar; 13(3):e069401. PubMed ID: 36914193
[TBL] [Abstract][Full Text] [Related]
2. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
[TBL] [Abstract][Full Text] [Related]
3. Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomised, prospective, multicentre, phase II trial (TORCH-C).
Zhang H; Li Y; Xia F; Sun Y; Shen L; Wan J; Chen Y; Wang Y; Zhou M; Wu R; Zhou S; Wang Y; Liu F; Cai S; Zhang Z
BMJ Open; 2024 Feb; 14(2):e079442. PubMed ID: 38309748
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
[TBL] [Abstract][Full Text] [Related]
5. Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
Huang W; Huang P; Guo H; Huang Z; Wei M; Guo J; Lin C; Li Y; Luo B; Lin J; Wang L
BMJ Open; 2023 Oct; 13(10):e075023. PubMed ID: 37798027
[TBL] [Abstract][Full Text] [Related]
6. Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial.
Zheng R; Wang BS; Li Z; Chi P; Xu B
BMJ Open; 2023 Mar; 13(3):e066976. PubMed ID: 36927585
[TBL] [Abstract][Full Text] [Related]
7. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial).
Pang K; Yang Y; Tian D; Zeng N; Cao S; Ling S; Gao J; Zhao P; Wang H; Kong Y; Zhang J; Chen G; Deng W; Bai Z; Jin L; Wu G; Zhu D; Wang Y; Zhou J; Wu B; Lin G; Xiao Y; Gao Z; Ye Y; Wang X; Li A; Han J; Yao H; Yang Y; Zhang Z
BMJ Open; 2023 Sep; 13(9):e069499. PubMed ID: 37699634
[TBL] [Abstract][Full Text] [Related]
8. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
[TBL] [Abstract][Full Text] [Related]
10. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.
Wu L; Yan H; Qin Y; Huang M; Wang T; Jin Q; Wei W
BMJ Open; 2024 Feb; 14(2):e075696. PubMed ID: 38341203
[TBL] [Abstract][Full Text] [Related]
11. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
[TBL] [Abstract][Full Text] [Related]
12. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study.
Xu T; Feng L; Zhang W; Li H; Ma H; Abulimiti M; Tan Y; Deng F; Huang W; Zou S; Kang W; Jiang L; Wang Y; Hu C; Chen Y; Zhou H; Tang Y; Jin J
BMC Cancer; 2024 Apr; 24(1):501. PubMed ID: 38641773
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Oncologic outcomes.
Cienfuegos JA; Rodríguez J; Baixauli J; Chopitea Ortega A; García-Consuegra A; Abengózar M; Sánchez Justicia C; Hernández Lizoain JL
Rev Esp Enferm Dig; 2020 Jan; 112(1):16-22. PubMed ID: 31729235
[TBL] [Abstract][Full Text] [Related]
15. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
[TBL] [Abstract][Full Text] [Related]
16. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
17. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
[TBL] [Abstract][Full Text] [Related]
18. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
Endo S; Terazawa T; Goto M; Tanaka R; Kato T; Fujitani K; Kawakami H; Sakai D; Kurokawa Y; Tsujinaka T; Shimokawa T; Satoh T
BMC Cancer; 2022 Jul; 22(1):811. PubMed ID: 35870893
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial.
Koike J; Funahashi K; Yoshimatsu K; Yokomizo H; Kan H; Yamada T; Ishida H; Ishibashi K; Saida Y; Enomoto T; Katsumata K; Hisada M; Hasegawa H; Koda K; Ochiai T; Sakamoto K; Shiokawa H; Ogawa S; Itabashi M; Kameoka S
Cancer Chemother Pharmacol; 2017 Mar; 79(3):519-525. PubMed ID: 28150022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
